Regulatory T Cell Therapeutics for Neuroinflammatory Disorders

Area of Science:

• Neuroimmunology
• Cellular immunology
• Neuroscience

Background:

• The central nervous system (CNS) relies on a delicate immune balance, often disrupted in neurological diseases, leading to neuroinflammation.
• Altered immune surveillance in the CNS can transform beneficial homeostatic signals into detrimental neuroinflammatory responses.
• Recent discoveries in immune cell subsets illuminate the complex interactions between the nervous and immune systems.

Approach:

• This review examines the role of regulatory T cells (Tregs), a T cell subset crucial for immune tolerance and neuroprotection.
• We explore the therapeutic potential of Tregs, drawing parallels with successful engineered T cell therapies like CAR T cells.
• The discussion focuses on the evolving application of Tregs in treating neuroinflammatory conditions.

Key Points:

• Regulatory T cells (Tregs) possess inherent immunosuppressive capabilities vital for maintaining immune tolerance.
• Tregs have demonstrated efficacy in various immune-related disorders, including graft-versus-host disease (GVHD), type 1 diabetes (T1D), and inflammatory bowel disease (IBD).
• The CNS environment is increasingly recognized as a target for Treg-based neuroprotective strategies.

Conclusions:

• Engineered Treg therapies present a promising frontier for neurological disease treatment, building on advancements in cell engineering.
• Understanding the immune system's role in neuroinflammation highlights Tregs as a key therapeutic target.
• This review synthesizes current knowledge on Tregs and their potential as treatments for neuroinflammatory disorders.